Ozempic vs Semaglutide: What’s the Difference?

Semaglutide is the drug; Ozempic is one brand name for it. It's the same relationship as ibuprofen and Advil. Every Ozempic pen contains semaglutide, but not everything sold as "semaglutide" is Ozempic. In the U.S., the FDA-approved brands are Ozempic and Ozempic tablets for type 2 diabetes, and Wegovy, the Wegovy pill and Wegovy HD for weight management. There's still no FDA-approved generic.

The confusion matters because "semaglutide" in an online ad usually means something else: a compounded or unregulated product that isn't Ozempic at all. Here's how to tell the difference.

Rybelsus, the original semaglutide pill, was replaced in the U.S. by Ozempic tablets on May 4, 2026, though it's still sold in other countries. The new tablets aren't dose-for-dose interchangeable with old Rybelsus strengths, so anyone switching should follow their prescriber's conversion.

Chemically, the semaglutide inside Ozempic and Wegovy is the same molecule. What makes Ozempic "Ozempic" is everything around it: an FDA-approved formula and manufacturing process, a specific pen and dose schedule, and an approved label for type 2 diabetes. A product that contains semaglutide but wasn't made by Novo Nordisk under that approval isn't Ozempic, even if the active ingredient is supposed to be identical.

So the honest answer is: Ozempic is semaglutide, but semaglutide isn't automatically Ozempic. The difference between Ozempic and Wegovy, two brands of the same molecule, is covered in our Ozempic vs Wegovy guide.

Not in the U.S. Novo Nordisk's patents keep generic semaglutide off the American market until at least the end of 2031, and possibly later because of additional patents on formulations and devices.

Other countries are ahead. In 2026, Health Canada approved several generic semaglutide products, including generic versions of Ozempic and, in June, of Wegovy. Generics are also sold in India. None of these are approved for sale in the U.S., and buying them from abroad comes with the same quality and legal questions as any imported prescription drug.

If you see "semaglutide" advertised by a telehealth company, med spa or website for a low monthly price, it's almost certainly one of these, and none of them are Ozempic:

The biggest practical risk with non-Ozempic semaglutide is the dose. Ozempic pens are set in milligrams. Vials come in different concentrations and are often measured in syringe "units," and FDA has documented overdoses from people drawing up 5 to 20 times the intended amount.

For years, the main reason people chose cheaper "semaglutide" was price. That gap has narrowed a lot. Novo Nordisk now sells Ozempic directly at $349 a month for doses up to 1 mg and $499 for 2 mg, Ozempic tablets start at $149, and the Wegovy pill starts at $149 for the lowest dose. With commercial insurance that covers it, the Ozempic savings card can bring the copay to as little as $25. For full price details, see our Ozempic cost guide.

One naming change in 2026 adds to the confusion: the oral semaglutide tablet formerly sold as Rybelsus is now branded Ozempic tablets, in new 1.5, 4 and 9 mg strengths. What changed, how the old doses convert and how the tablet differs from the injection and the Wegovy pill is covered in Ozempic tablets: what changed when Rybelsus became Ozempic.

Semaglutide is the active ingredient; Ozempic is Novo Nordisk's approved brand of it for type 2 diabetes, alongside Ozempic tablets and the Wegovy family for weight management. There's no U.S. generic yet. When something is sold simply as "semaglutide," assume it isn't Ozempic until you know exactly who made it and how it's dosed.